Comprehensive Stock Comparison
Compare SRx Health Solutions Inc. (SRXH) vs Agios Pharmaceuticals, Inc. (AGIO) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | AGIO | 48.0% revenue growth vs SRXH's 28.4% |
| Quality / Margins | SRXH | -9.4% net margin vs AGIO's -9.0% |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | AGIO | -14.9% vs SRXH's -94.0% |
| Efficiency (ROA) | SRXH | -22.4% ROA vs AGIO's -29.0%, ROIC -18.1% vs -26.6% |
Who Each Stock Is For
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
SRx Health Solutions is an integrated Canadian healthcare services provider that offers comprehensive specialty healthcare services across all ten provinces. It generates revenue primarily through its specialty pharmacy services — which include medication dispensing and patient support programs — and its health solutions segment that provides clinical services and chronic disease management. The company's competitive advantage lies in its integrated, technology-enabled platform that combines pharmacy services with clinical care, creating a patient-centric ecosystem that's difficult for traditional pharmacies to replicate.
Agios Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare genetic diseases related to cellular metabolism. It generates revenue primarily from sales of its lead drug PYRUKYND for pyruvate kinase deficiency — with additional income from research collaborations and milestone payments — while advancing a pipeline of other metabolic therapies. The company's competitive advantage lies in its deep expertise in cellular metabolism science and proprietary platform for targeting metabolic pathways in rare diseases.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
SRXH leads in 2 of 6 categories (Financial Metrics, Profitability & Efficiency). AGIO leads in 1 (Total Returns). 2 tied.
Financial Metrics (TTM)
SRXH is the larger business by revenue, generating $119M annually — 2.7x AGIO's $45M. Profitability is closely matched — net margins range from -9.4% (SRXH) to -9.0% (AGIO).
| Metric | SRXHSRx Health Soluti… | AGIOAgios Pharmaceuti… |
|---|---|---|
| RevenueTrailing 12 months | $119M | $45M |
| EBITDAEarnings before interest/tax | — | -$470M |
| Net IncomeAfter-tax profit | — | -$401M |
| Free Cash FlowCash after capex | — | -$414M |
| Gross MarginGross profit ÷ Revenue | +19.9% | +84.4% |
| Operating MarginEBIT ÷ Revenue | -4.9% | -10.6% |
| Net MarginNet income ÷ Revenue | -9.4% | -9.0% |
| FCF MarginFCF ÷ Revenue | +1.3% | -9.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +43.7% |
| EPS Growth (YoY)Latest quarter vs prior year | — | -111.0% |
Valuation Metrics
| Metric | SRXHSRx Health Soluti… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Market CapShares × price | $9M | $2.25T |
| Enterprise ValueMkt cap + debt − cash | $36M | $2.25T |
| Trailing P/EPrice ÷ TTM EPS | -0.19x | -4.25x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.10x | 9999.00x |
| Price / BookPrice ÷ Book value/share | — | 1.47x |
| Price / FCFMarket cap ÷ FCF | 7.56x | — |
Profitability & Efficiency
| Metric | SRXHSRx Health Soluti… | AGIOAgios Pharmaceuti… |
|---|---|---|
| ROE (TTM)Return on equity | — | -31.2% |
| ROA (TTM)Return on assets | -22.4% | -29.0% |
| ROICReturn on invested capital | -18.1% | -26.6% |
| ROCEReturn on capital employed | -98.8% | -33.8% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | — | 0.03x |
| Net DebtTotal debt minus cash | $37M | -$49M |
| Cash & Equiv.Liquid assets | $2M | $89M |
| Total DebtShort + long-term debt | $39M | $40M |
| Interest CoverageEBIT ÷ Interest expense | -2.83x | — |
Total Returns (with DRIP)
A $10,000 investment in AGIO five years ago would be worth $6,363 today (with dividends reinvested), compared to $599 for SRXH. Over the past 12 months, AGIO leads with a -14.9% total return vs SRXH's -94.0%. The 3-year compound annual growth rate (CAGR) favors AGIO at 6.1% vs SRXH's -60.9% — a key indicator of consistent wealth creation.
| Metric | SRXHSRx Health Soluti… | AGIOAgios Pharmaceuti… |
|---|---|---|
| YTD ReturnYear-to-date | -47.4% | +11.2% |
| 1-Year ReturnPast 12 months | -94.0% | -14.9% |
| 3-Year ReturnCumulative with dividends | -94.0% | +19.4% |
| 5-Year ReturnCumulative with dividends | -94.0% | -36.4% |
| 10-Year ReturnCumulative with dividends | -94.0% | -21.2% |
| CAGR (3Y)Annualised 3-year return | -60.9% | +6.1% |
Risk & Volatility
SRXH is the less volatile stock with a -1.27 beta — it tends to amplify market swings less than AGIO's 0.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AGIO currently trades 65.7% from its 52-week high vs SRXH's 5.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SRXHSRx Health Soluti… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -1.27x | 0.91x |
| 52-Week HighHighest price in past year | $2.16 | $46.00 |
| 52-Week LowLowest price in past year | $0.08 | $22.24 |
| % of 52W HighCurrent price vs 52-week peak | +5.8% | +65.7% |
| RSI (14)Momentum oscillator 0–100 | 43.4 | 62.3 |
| Avg Volume (50D)Average daily shares traded | 27.2M | 948K |
Analyst Outlook
| Metric | SRXHSRx Health Soluti… | AGIOAgios Pharmaceuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $41.50 |
| # AnalystsCovering analysts | — | 29 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| SRx Health Solution… (SRXH) | $93M | $119M | +28.4% |
| Agios Pharmaceutica… (AGIO) | $70M | $54M | -22.7% |
Agios Pharmaceuticals, Inc.'s revenue grew from $70M (2016) to $54M (2025) — a -2.8% CAGR.
Chart 2Net Margin Trend — 10 Years
| Stock | 2014 | 2025 | Change |
|---|---|---|---|
| SRx Health Solution… (SRXH) | -2.6% | -9.4% | -254.1% |
| Agios Pharmaceutica… (AGIO) | -81.9% | -7.6% | +90.7% |
Agios Pharmaceuticals, Inc.'s net margin went from -82% (2014) to -8% (2025).
Chart 3EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| SRx Health Solution… (SRXH) | -3.48 | -0.9 | +74.1% |
| Agios Pharmaceutica… (AGIO) | -5.07 | -7.12 | -40.4% |
Agios Pharmaceuticals, Inc.'s EPS grew from $-5.07 (2016) to $-7.12 (2025).
Chart 4Free Cash Flow — 5 Years
SRx Health Solutions Inc. generated $2M FCF in 2023 (-50% vs 2022). Agios Pharmaceuticals, Inc. generated $-377M FCF in 2025 (+9% vs 2021).
SRXH vs AGIO: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is SRXH or AGIO a better buy right now?
Analysts rate Agios Pharmaceuticals, Inc. (AGIO) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SRXH or AGIO?
Over the past 5 years, Agios Pharmaceuticals, Inc. (AGIO) delivered a total return of -36.4%, compared to -94.0% for SRx Health Solutions Inc. (SRXH). A $10,000 investment in AGIO five years ago would be worth approximately $6K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AGIO returned -21.2% versus SRXH's -94.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SRXH or AGIO?
By beta (market sensitivity over 5 years), SRx Health Solutions Inc. (SRXH) is the lower-risk stock at -1.27β versus Agios Pharmaceuticals, Inc.'s 0.91β — meaning AGIO is approximately -171% more volatile than SRXH relative to the S&P 500.
04Which has better profit margins — SRXH or AGIO?
SRx Health Solutions Inc. (SRXH) is the more profitable company, earning -9.4% net margin versus -764.0% for Agios Pharmaceuticals, Inc. — meaning it keeps -9.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SRXH leads at -4.9% versus -873.9% for AGIO. At the gross margin level — before operating expenses — AGIO leads at 88.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — SRXH or AGIO?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is SRXH or AGIO better for a retirement portfolio?
For long-horizon retirement investors, SRx Health Solutions Inc. (SRXH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -1.27)). Both have compounded well over 10 years (SRXH: -94.0%, AGIO: -21.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between SRXH and AGIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.